SCHEMBL21137927

SCHEMBL21137927

CCCC(=O)N[C@H]1C(C)O[C@H](COC(=O)OC(CO)CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGB P11216 1/20 0.41
▸ PRKD3 O94806 1/20 0.36
▸ PRKCG P05129 1/20 0.36
▸ PRKCB P05771 1/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ PRKCH P24723 1/20 0.36
▸ PRKCI P41743 1/20 0.36
▸ PRKCE Q02156 1/20 0.36
▸ PRKCQ Q04759 1/20 0.36
▸ PRKCZ Q05513 1/20 0.36
▸ PRKCD Q05655 1/20 0.36
▸ PRKD1 Q15139 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ NEU4 Q8WWR8 1/20 0.33
▸ NEU1 Q99519 1/20 0.33
▸ NEU3 Q9UQ49 1/20 0.33
▸ NEU2 Q9Y3R4 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ TLR4 O00206 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137918 0.90 PYGB (0.41) PYGBPRKD3PRKCGPRKCBPRKCA
SCHEMBL21137906 0.82 PYGB (0.44) PYGBPRKD3PRKCGPRKCBPRKCA
SCHEMBL21137875 0.78 PYGB (0.40) PYGBMAPK1L3MBTL1
SCHEMBL21058377 0.78 PYGB (0.40) PYGBPRKD3PRKCGPRKCBPRKCA
SCHEMBL21137865 0.78 PYGB (0.64) PYGBALDH1A1THRBMAPK1L3MBTL1
SCHEMBL18391212 0.78 PYGB (0.64) PYGBALDH1A1THRBMAPK1L3MBTL1
SCHEMBL23104924 0.78 PYGB (0.38) PYGBPRKD3PRKCGPRKCBPRKCA
SCHEMBL21137873 0.76 PYGB (0.39) PYGBALDH1A1THRBMAPK1L3MBTL1
SCHEMBL21137919 0.76 PYGB (0.39) PYGBL3MBTL1
SCHEMBL21138646 0.76 PYGB (0.38) PYGBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA PYGB 760/4885PRKD3 3161/4885PRKCG 4058/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA PYGB 760/4885PRKD3 3161/4885PRKCG 4058/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885PRKD3 3037/4885PRKCG 3291/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885PRKD3 3037/4885PRKCG 3291/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA PYGB 601/4885PRKD3 3037/4885PRKCG 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback